cardiotoxicity


Also found in: Wikipedia.

cardiotoxicity

/car·dio·tox·ic·i·ty/ (kahr″de-o-tok-sis´ĭ-te) the quality of being cardiotoxic.

cardiotoxicity

A deleterious effect on the heart. See Cocaine cardiotoxicity.

cardiotoxicity

drug-induced suppression of heart muscle or its conduction system, e.g. local anaesthetic overdose
References in periodicals archive ?
Cancer drug discovery Sci-Engi-Medco Solutions Inc reported on Friday the receipt of a Small Business Innovation Research (SBIR) Phase 1 contract from the National Cancer Institute (NCI) titled "Theranostics of Reduction of Cardiotoxicity Using Targeted Apoptosis Activation Technology" for preclinical model of triple negative breast cancer.
Cardiotoxicity probably due to 5-FU was suspected and chemotherapy discontinued from day 3.
However, the ability to provide patients with optimal treatment exposure to doxorubicin is limited due to the risk of patients developing irreversible cardiotoxicity.
Our review defines that the price of treatment for childhood cancer for many survivors is persistent, often progressive, and pervasive cardiotoxicity for those treated with anthracycline chemotherapy, said Dr.
a) There are no conclusive data to predict that patients will develop cardiotoxicity
All of these findings suggest tricyclic antidepressant cardiotoxicity.
The occurrence of fatal cardiotoxicity in pediatric as well as in adult patients is characterized by an irreversible cardiomyopathy which compromises the clinical utility of DOX and accounts for the major cause of the chemotherapy related morbidity and mortality [1].
The most serious side effect of anthracyclines is cardiotoxicity.
Cardiotoxicity was induced by single intravenous injection of 12 mg/kg of doxorubicin in a group of rabbits control group was treated with normal saline only and the rabbits of third group were pretreated with a- Tocopherol 200 mg/kg of body weight for ten days before injection of doxorubicin 12 mg/kg.
Although cardiovascular complications from IFN-[alpha] are scarce, the growing number of patients receiving Peg IFN-[alpha] therapy will undoubtedly lead to an increasing number of patients with cardiotoxicity.
Among specific topics are atrial fibrillation and cardiomyopathy with heart failure, cardiac resynchronization therapy, evaluating and managing the heart transplant candidates, the cardiotoxicity of anti-cancer treatment, and the role of risk modeling in heart failure.

Full browser ?